Compare AstraZeneca plc (AZN) vs Gogoro Inc (GGR) Price & Performance

AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.

The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.

GGR trades at $3.88, up 0.78% on the day, while showing bearish technical signals with a negative net income margin of -24.68% and ROE of -50.38% for 2025. The company reported revenue of $281.48M but a net loss of $79.97M, though cash flow from operations improved to $35.90M. Recent news highlights a private placement and Q1 2026 results emphasizing margin improvement and growth plans.

Outlook remains challenged by persistent losses and negative profitability metrics, offset by operational discipline and subscriber growth. Key risks include execution on profitability, competitive pressures, and cash flow sustainability. Analysts are neutral with 100% hold ratings, reflecting cautious optimism amid fundamental headwinds.